Chaga Mushroom for Blood Sugar Regulation

Research suggests that Chaga mushroom (Inonotus obliquus) and several of its isolated compounds — including polysaccharides, betulinic acid, and inotodiol — may help reduce blood glucose levels, improve insulin sensitivity, normalize blood lipid profiles, and protect against diabetes-related kidney damage, based on a consistent body of animal studies. Studies indicate these effects may operate through multiple biological pathways, including activation of metabolic signaling cascades in the liver (PI3K/Akt and AMPK/ACC), modulation of inflammatory markers, inhibition of carbohydrate-digesting enzymes, and — in more recent work — favorable shifts in gut microbiome composition and short-chain fatty acid production. All twelve studies reviewed were conducted in rodent models, typically using diet- and drug-induced diabetes, and none were human clinical trials, meaning the findings cannot yet be directly applied to people. The overall direction of the evidence is supportive, but the absence of randomized controlled trials in humans represents a significant limitation, and further research is needed before any conclusions about efficacy or safety in people can be drawn.